Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Equity Income (2022 - 2024)

Caribou Biosciences has reported Equity Income over the past 3 years, most recently at -$14000.0 for Q3 2024.

  • Quarterly Equity Income fell 250.0% to -$14000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$125000.0 through Sep 2024, down 119.3% year-over-year, with the annual reading at -$6000.0 for FY2023, 95.49% up from the prior year.
  • Equity Income was -$14000.0 for Q3 2024 at Caribou Biosciences, up from -$102000.0 in the prior quarter.
  • Over five years, Equity Income peaked at $31000.0 in Q3 2022 and troughed at -$102000.0 in Q2 2024.
  • The 3-year median for Equity Income is -$14500.0 (2023), against an average of -$25500.0.
  • Year-over-year, Equity Income soared 237.5% in 2023 and then tumbled 563.64% in 2024.
  • A 3-year view of Equity Income shows it stood at -$60000.0 in 2022, then surged by 85.0% to -$9000.0 in 2023, then plummeted by 55.56% to -$14000.0 in 2024.
  • Per Business Quant, the three most recent readings for CRBU's Equity Income are -$14000.0 (Q3 2024), -$102000.0 (Q2 2024), and -$9000.0 (Q4 2023).